Roche breast cancer experimental drug granted priority review
Feb 7, 2012
U.S. health officials announced that they will grant a priority review for a Roche experimental drug, which held off the disease for six months after the treatment until it started to worsen.
The drug, pertuzumab, will either be approved or denied by the U.S. Food and Drug Administration on June 8.
If approved, pertuzumab will be prescribed to patients with advanced HER2-positive breast cancer who have received no treatment or had recurrence after surgery.
"We have been researching HER2-positive breast cancer for more than 30 years, and we hope an expedited review will help us quickly bring another personalized medicine to people battling this aggressive disease," said Hal Barron, Roche's chief medical officer.
According to the American Cancer Society, one in eight women in the U.S. will be diagnosed with breast cancer at some point during her lifetime. It is recommended that once a woman turns 40, she schedules an annual mammogram to ensure that she does not have the disease, and if she does - they detect it early on.